News

Our Healthcare News

Grupo Biotoscana Expands Partnership with Gilead Sciences in HCV in Brazil

Montevideo, Uruguay—GBT-Grupo Biotoscana (B3: GBIO33), a leading specialty pharmaceutical company in Latin America, today announced that it has expanded its partnership with Gilead Sciences (Nasdaq:…  

Aug 30 2017

AxoGen, Inc Reports 2017 Second Quarter Financial Results, Representing 46% Growth over Prior Year

ALACHUA, Fla., (GLOBE NEWSWIRE)—AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and…  

Aug 02 2017

Abiomed Announces Q1 FY 2018 Revenue of $132.5 Million, Up 29% Over Prior Year

DANVERS, Massachusetts—  Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today reported first quarter fiscal 2018 revenue of $132.5 million, an…  

Jul 27 2017

Grupo Biotoscana Raises $417 Million in Oversubscribed Brazil IPO

LONDON, United Kingdom—EW Healthcare Partners (“EWHP”), a global healthcare growth equity investor, announced that Grupo Biotoscana (“Biotoscana”), a Pan-Latin American specialty pharmaceutical company focused on…  

Jul 21 2017

Venus Concept Closes $38 Million Equity Financing to Support Continued Growth Opportunities

TORONTO, Canada—Venus Concept Ltd., a privately-held and innovative global aesthetic technology leader, today announced the closing of a $38 million equity investment. The equity investment…  

Jul 13 2017

EUSA Pharma Receives Positive CHMP Opinion for Tivozanib for First-Line Treatment

HEMEL HEMPSTEAD, England – – EUSA Pharma (EUSA), a specialty pharmaceutical company with a focus on oncology and oncology supportive care, today announced that the…  

Jun 23 2017

Endologix Provides an Update on the Nellix Endovascular Aneurysm Sealing System US Regulatory Status

IRVINE, California – Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that the Company met with the…  

May 17 2017

European Commission Approves the Only Immunotherapy for High-Risk Neuroblastoma

HEMEL HEMPSTEAD, England – EUSA Pharma today announced that the European Commission (EC) has approved the antibody ch14.18/CHO, dinutuximab beta, for the treatment of high-risk…  

May 09 2017

EUSA Pharma and Apeiron Biologics Receive Positive CHMP Opinion for Dinutuximab Beta

HEMEL HEMPSTEAD, England and VIENNA, Austria – – EUSA Pharma (EUSA), a specialty pharmaceutical company with a focus on oncology and oncology supportive care, and…  

Mar 27 2017



View Legacy Fund news >